Opinion
Numbers behind different COVID-19 vaccines
By M. C. M. Iqbal
The vaccines against COVID-19, available today, are based on different strategies and come with different numbers to indicate their performance. Many of us wish to know if one vaccine is better than the other. Two concepts underlying the performance of the vaccines are efficacy and effectiveness. The Pfizer-BioNTech vaccine has an efficacy of 95 percent, the Moderna Vaccine is 94.5 percent and the Russian made Sputnik vaccine is over 90 percent. Does this mean some vaccines are better than the other? The short answer is no. All the approved vaccines are equally good. So, let us look at what these numbers mean.
These numbers refer to statistical calculations to interpret the results of vaccination trials conducted by the manufacturers of vaccines, following a prescribed format. The method of calculation was developed over 100 years ago by two statisticians, who published their results in the Proceedings of the Royal Society of Medicine in 1915. They, Major Greenwood (Major is his first name and not a military title) and Udny Yule, were tasked with interpreting the results of immunization of British soldiers against typhoid and cholera, who were fighting in different regions of Europe and Asia favourable to the development of cholera epidemics. In a paper stretching over 82 pages, the authors developed the theoretical and mathematical background for calculating the efficacy of vaccines.
This article seeks to explain to the lay reader what these numbers imply and to bring out the differences between efficacy and effectiveness of a vaccine.
Efficacy and effectiveness
At first sight these two terms appear to be synonyms. However, in the world of vaccines and medicine, these two terms are not the same. Efficacy of a vaccine is how it performs under ideal and controlled conditions in a clinical trial (see below). During clinical trials, the outcome of vaccination is compared between a group of vaccinated people and another group given an inactive form of the vaccine (called a placebo). The effectiveness of a vaccine is how the vaccine performs in the real world – that is after the vaccine is approved by the regulatory agencies and you and I are vaccinated.
The efficacy of a vaccine is measured by the manufacturers under ideal conditions in a clinical trial where criteria are specified for selecting and excluding volunteers. These criteria are usually age groups, gender, ethnicity, geographical location and socio-economic standing. If the criteria are specific, then the effects of the vaccine or drug would not be applicable across the population. For example, if the COVID-19 vaccines are not tested on children below 18 years, then the approved vaccine cannot be used on children.
The effectiveness of a drug or vaccine is a measure of how well the drug or vaccine performs in real life, in a diverse population: Fitness geeks and couch potatoes, housewives and nurses, and farmers and office workers. Effectiveness is of relevance to the medical community and healthcare authorities who are treating the patients. Thus, studies on effectiveness would look at to what extent the vaccine is beneficial to the patient to prevent infection.
One may ask, why not simply look at the effectiveness of the vaccine? This is because if the participants in an initial trial of the vaccine are not carefully controlled, then it is difficult to interpret the outcome of the trial. We have many characteristics, which can potentially interfere with the outcome of a trial testing a vaccine. The person volunteering for the trial could be young or old, pregnant or not, a marathon runner or an average person and smoker or non-smoker. Thus, the volunteers selected for the trials are very similar within their groups with many criteria to exclude persons who could confuse the results (for example, an unhealthy person with other diseases would be excluded).
Efficacy of a vaccine asks the question ‘Does the vaccine work under ideal conditions?’ On the other hand, a study on the effectiveness of the same vaccine asks the question ‘Does vaccination work in the real world?’
Clinical trials
Under normal circumstances, vaccines take many years of research and testing to be approved. The COVID-19 pandemic was unprecedented, and pharmaceutical companies embarked on a race against time to produce safe and effective vaccines. The genome of this coronavirus, which was discovered by Chinese scientists, in January 2020, was a major contribution to the development of the vaccines. At the moment there are 94 vaccines being tested on humans in clinical trials, 32 of which have reached the final stage of Phase 3 testing.
To obtain approval for a vaccine, the vaccine manufacturers go through a prescribed process to ensure that the vaccine is safe. All the countries have a national drug approval agency, who should approve the use of a drug or vaccine in that country. The Food and Drug Administration (FDA) in the United States is an important regulatory agency, which has stringent criteria to approve medicines and drugs. In Sri Lanka, it is the National Medicines Regulatory Authority. COVID-19 vaccines are also assessed and approved by the WHO.
Initially, the vaccine is tested on cells in the laboratory and then given to animals, usually mice or monkeys. After this, if the mice or monkeys are happy, human volunteers are recruited to conduct the clinical trials, which is done in three phases. In the first phase, the vaccine is tested on a small group of people to determine the safety, dosage and ability to stimulate our immune system. If this is confirmed, the vaccine then moves into the Phase 2 stage where the safety of the vaccine is tested on hundreds of people who are split into different groups. Once these trials are successful, the vaccine moves to the final Phase 3 trials. Here thousands of people are recruited as volunteers. For the Pfizer-BioNTech vaccine there were over 40,000 volunteers, above the age of 16, from different countries. This trial is more comprehensive, with the volunteers belonging to different age groups, physical fitness, ethnicities and geographical locations. The volunteers are divided into two groups. One group gets the real vaccine while the other group gets a fake vaccine or placebo (the syringe has just water). The volunteers would not know if he/she is getting the vaccine or a placebo and neither do the nurses and doctors giving the vaccine. This is called a double-blind clinical trial. Thus, no one knows, except those conducting the trial, who was vaccinated with what.
After some time, the volunteers, who fell sick with the coronavirus, are PCR tested to confirm if they are COVID-19 positive. The scientists will be on the lookout for any side effects of the vaccine; if they find any cause for concern the trial can be stopped temporarily to conduct investigations and remedy the problem. If the scientists are not satisfied, the trial would be abandoned. Once the results are in, the calculations are done, and all the details are submitted to the regulating authorities. The regulators would ask the manufacturers more questions and once they are satisfied, approval is given to manufacture and market the vaccine. To accelerate the process, such as now during the COVID-19 crises, Phase 1 and 2 may be combined and run in parallel.
Calculating efficacy
The calculations involved are quite simple once the data is collected. Let us assume that 50,000 volunteers were recruited for the vaccination trial. Half were given the vaccine and the other half a placebo. Let us assume that of the 25,000 who received the vaccine, 10 persons were infected, and of the other 25,000 who received the placebo, 200 were infected. Although the numbers of people infected are small, those in the placebo group are 20 times larger (see Table). The researchers are concerned with the relative risk between the groups. This is called the efficacy of the vaccine.

The risk of infection is calculated as follows.
What is the difference in the risk of infection between the vaccinated group and those who got the placebo? From the table this is, 0.80 percent – 0.04 percent = 0.76 percent.
Thus, the vaccine reduced the risk of infection by 0.76 percent, which looks quite small. This is what would happen if we are vaccinated. To understand this in terms of the risk of infection, if none were vaccinated, we look at the ratio of the Reduction in Infection (0.76 percent) to the Risk of infection (0.80 percent – those who got the fake vaccine). This is the Vaccine Efficacy (VE).
VE percent = Reduction in infection ÷ Risk of infection = 0.76 ÷ 0.80 = 95 percent
If this is still confusing, let us see what it means in a population of 100,000 persons who are vaccinated with a vaccine of 95 percent efficacy, and exposed to the virus. From the table above, the risk of infection for the vaccinated population is 0.04 percent, which translates to 40 persons (0.04 percent x 100,000). That is, we can expect that 40 persons would fall ill with an infection by the coronavirus and the rest of the vaccinated people may not develop an infection at all or develop an asymptomatic infection (you are infected but do not show symptoms) or get a mild disease.
(This example of calculating Vaccine Efficacy is adapted from an article by Dashiell Young-Saver in the New York Times of December 13, 2020, where the above calculation is explained in detail for students.)
What does efficacy mean?
The efficacy of a vaccine refers to two aspects. The first is how many of us are protected by the vaccine if we are exposed to the virus; this is given by the percentage. The vaccine also refers to different disease conditions it is capable of preventing. This could be causing an infection, mild disease, severe disease, hospitalisation, or death. This information can be found if one looks carefully at the statements issued by the vaccine manufacturer and regulatory agencies. For example, the statement by Pfizer-BioNTech states: Pfizer-BioNTech COVID-19 vaccine, BNT162b2, was 91.3 percent effective against COVID-19 (symptomatic cases of COVID-19), measured seven days through up to six months after the second dose. The vaccine was 100 percent effective against severe disease as defined by the US centres for Disease Control and Prevention (CDC), and 95.3 percent effective against severe disease as defined by the US FDA.
The efficacy of a vaccine (VE) is the relative reduction of being infected, if we are vaccinated, compared to the placebo or unvaccinated group. If the vaccine is perfect, then the risk of being infected is totally eliminated, so that VE = 1 or it is 100 percent. On the other hand, if there is no difference in the number of people infected between the two groups, the vaccine has no efficacy, or it is zero. Even with a perfect vaccine, our capacity to acquire an infection is determined by our age, health and immunity status.
In short, efficacy is a statistical measurement based on clinical trials of the vaccine’s ability to prevent infection. The volunteers taking part in the trials are not a perfect sample or representative of the real world (for example, children and sick people do not take part). Is there a lower limit for the efficacy of a vaccine to be accepted? Under the present circumstances, the FDA said it would consider granting emergency approval if the vaccines showed even 50 percent efficacy; the vaccines that have received approval now show an efficacy of over 90 percent.
Effectiveness
The effectiveness of the vaccine tells us how well the vaccine is performing among the population, in the real world, to prevent infection. The effectiveness of the vaccine depends on the impact it makes on society. After vaccination our immune system is primed to combat the coronavirus, reducing the multiplication of the virus in our body. This will gradually slow down the spread of the virus as more and more people are vaccinated. In other words, it is important that most if not all the people are vaccinated to have a large impact on the spread of the virus in society. Good examples are the smallpox vaccine, which completely eliminated the smallpox virus, and the polio vaccine, which has almost wiped out the polio virus except for a few small pockets in Pakistan, Afghanistan and Africa. Thus, the effectiveness of a vaccine looks at the medical and societal importance of the outcome.
Here is the above in a nutshell. The percentage numbers given with a vaccine refers to its efficacy – its ability to prevent an infection developing into a serious condition, determined under controlled clinical trials. Vaccines do not prevent infection – they prevent the infection from developing into a severe disease. Once we are vaccinated, our immune system is activated. If we are infected by the coronavirus, the virus has a small window of time to multiply, before it is eliminated by our immune system. This means we can release virus particles from our body, but much less than if we were not vaccinated. The message is we should get vaccinated with the first available vaccine and still wear our masks when going outside, even if we are vaccinated. The chances of ending up in a hospital is low and the chances of ending up in the ICU is very low. There is always a chance.
‘Tis impossible to be sure of anything but Death and Taxes (Christopher Bullock, 1716).
(M.C.M. Iqbal is Associate Research professor, Plant and Environmental Science, National Institute of Fundamental Studies, Hanthane Road, Kandy, and can be reached at iqbal.mo@nifs.ac.lk)
References
Zimmer, C. New York Times Nov. 20, 2020. Two companies say their vaccines are 95 percent effective. What does that mean?
Haelle,T. Association of Health Care Journalists. October 22, 2020. Know the nuances of vaccine efficacy when covering Covid-19 trials. https://healthjournalism.org/blog/2020/10/know-the-nuances-of-vaccine-efficacy-when-covering-covid-19-vaccine-trials/
Greenwood, M., & Yule, G. U. (1915). The Statistics of Anti-typhoid and Anti-cholera Inoculations, and the Interpretation of such Statistics in general. Proceedings of the Royal Society of Medicine, 8 (Sect Epidemiol State Med), 113–194.
Food and Drug Administration, US Department of Health and Human Services. https://www.fda.gov/media/139638/download
Opinion
In Memory of Dr Upatissa Pethiyagoda
It is with a deep sense of sadness that I record the passing of Dr Upatissa Pethiyagoda, who died on 27 August 2026 at the age of 94. To many, he was a distinguished scientist, accomplished administrator, diplomat and public intellectual. To me, he was much more than that.
Dr Pethiyagoda was a proud product of Trinity College, Kandy. At a time when a first class in Botany was a rarity, he obtained one and subsequently pursued postgraduate studies in London. His scientific career reflected not only his knowledge but, more importantly, an enquiring and restless mind that was never satisfied with simply accepting what was known.
In the 1970s, he headed the Plant Physiology Department of the Tea Research Institute of Sri Lanka. He was part of a formidable team of scientists that included Drs R L de Silva, R L Wickramasinghe, P Sivapalan, Tilak Wettasinghe and W Danthanarayana. They were scientists who contributed enormously to the development of the tea industry in Sri Lanka, and Dr Pethiyagoda stood comfortably among them.
In 1978, he moved to the Coconut Research Institute as its Director. It was there that I had the privilege of working with him. Those years left a lasting impression on me.
Dr Pethiyagoda was, in every sense, a complete scientist. Although his formal specialisation was plant physiology, he was remarkably comfortable discussing almost anything scientific. What distinguished him was his curiosity. He questioned the science behind the ordinary things that most of us simply accepted. I remember his asking questions such as, why is an orange green in Sri Lanka? It was typical of him: an apparently simple observation would lead him to ask what lay behind it.
That curiosity never left him.
After his tenure at the CRI, he undertook an FAO assignment in the Middle East, working on the improvement of date palms. There he was exposed to agriculture under conditions of severe water scarcity. He pursued this further during a visit to Israel, learning about agronomic practices suited to such environments. Later, when he worked with the Mahaweli Authority, he was able to translate that knowledge into practice, introducing high-value horticultural crops to Systems B and C.
What impressed me was not merely that he acquired knowledge, but that he connected knowledge from one context to another and turned it into practical solutions. His enquiring mind and analytical ability enabled him to do this with remarkable effectiveness.
He was equally impressive as a communicator. Dr Pethiyagoda was an eloquent speaker, whether he was talking about science, agriculture, public policy or the everyday affairs of our country. His speeches were often laced with wit, humour and the occasional tongue-in-cheek remark. But beneath the humour was a very serious mind. He was forthright in his opinions and, importantly, he was not afraid to express them, whatever the possible repercussions.
His contributions to the media demonstrated this courage.
Writing about the travel to London by a former President, he observed:
“Where a person enjoys immunity by virtue of his position, this carries a reciprocal obligation to exercise an abundance of exemplary behaviour. In effect, immunity is best exercised, when the need to invoke it, is never allowed to arise.”
[Immunity Does Not Confer Impunity – Colombo Telegraph]
That was quintessential Pethiyagoda—precise, pointed and impossible to misunderstand.
He was equally outspoken about the government’s decision to ban inorganic fertiliser with ‘immediate effect’. He was deeply distressed by what he believed would be the consequences for farmers, particularly the poorer farming community. He would speak about it almost every day, driven not by political considerations but by his conviction that science and evidence had been disregarded.
In one of his writings on the subject, he remarked:
“What the ‘Vipathmaga’ caper taught us was that advice of sundry ‘Experts’ can be disastrous. Professors of Surgery, clergymen and Pediatricians are not the best equipped to advise on fertilisers, as much as a Soil Scientist should not prescribe treatment for a sick child.’ [Some Lessons That Can Be Learned Even From Disasters – Colombo Telegraph]
And in another article, his frustration was summed up in the memorable words:
“Stupidity, like History, has a way of repeating itself.”
[Unscrambling eggs – Colombo Telegraph]
These were not simply provocative statements. They reflected a scientist who believed deeply that public decisions, particularly those affecting agriculture and the livelihoods of farmers, should be based on evidence and sound scientific advice.
Perhaps, what I will remember most about Dr Pethiyagoda is that his curiosity survived almost to the very end of his life.
Very recently, he was still asking questions and pursuing ideas. He was interested in the possible genetic differences between the waraka and wela varieties of jak, because he wondered whether the wela variety might have commercial potential for cellulose extraction. He was disappointed that he could not find relevant scientific literature in Sri Lanka. More than the particular subject, what struck me was that at 94 he was still thinking about a scientific question, looking for evidence and wondering whether an apparently ordinary resource could have an important national application. He lamented the lack of interest among scientists and academics in such questions of national importance. That concern, too, was very much part of who he was.
Dr Pethiyagoda also served as President of the National Academy of Sciences, Sri Lanka. Unfortunately, he was unable to complete his term because he was appointed Ambassador to Italy, with representation at the Food and Agriculture Organization in Rome. Even in that role, he remained very much the scientist. I understand that he made a significant contribution to FAO discussions. As Ambassador, he also had the unenviable task of entertaining Sri Lankan Ministers of Agriculture who attended FAO sessions. I know from my own conversations with him that those informal dinners were not merely social occasions. He would discuss agricultural issues with the Ministers, and I have little doubt that his views—and the force with which he expressed them—sometimes influenced their thinking.
Looking back, what I admired most about Dr Pethiyagoda was not any particular position he held or any particular achievement. It was the way he thought.
He questioned.
He analysed.
He connected ideas.
He challenged conventional wisdom.
And he was willing to say what he believed to be true.
He also demonstrated that science should not remain confined to laboratories, research papers or academic institutions. For him, science was a way of looking at the world and, ultimately, a means of improving the lives of people.
It is perhaps ironic that, only a few months ago, he wrote about “The Cost of Dying”, as distinct from the “Cost of Living”. In that article, he reflected on the manner in which our mortal remains should be disposed of, observing: “I am in two minds regarding the manner in which the mortal remains are disposed of, ‘according to the will of the deceased’. But with the cessation of the breath, ownership or tenancy ceases.” Even in contemplating death, he brought his characteristic questioning mind to the subject. What particularly caught my attention, however, was his explanation of the Buddhist practice of holding dânes (almsgivings) for monks of the local temple in the seventh day and third month following a death. I had never really thought about the significance of this practice before. That, too, was typical of Dr Pethiyagoda: he could take something that we had accepted as ordinary and familiar and make us stop, think and see it differently.
His passing has created a colossal vacuum in Sri Lanka’s scientific community. People of his intellectual breadth, curiosity, courage and independence are rare. We may not always have agreed with everything he said, but we could never doubt that he had thought deeply about it and that he had the courage of his convictions.
For those of us who had the privilege of knowing him, there is sadness in his passing. But there is also gratitude—for having known such an extraordinary mind, for having learnt from him, and for having witnessed at close quarters his unwavering commitment to science and to the development of our country.
I shall remember Dr Pethiyagoda with great affection and immense respect.
Ranjith Mahindapala
Past President, National Academy of Sciences of Sri Lanka.
Opinion
A neighbour’s view of India’s strategic strengths
What India chooses to do with the strategic freedom it has built over eight decades may be the defining question of its next phase
by Milinda Moragoda
In the emerging global economy, countries will increasingly seek multiple sources of energy, technology, capital, minerals and markets. India can contribute by helping create an open network rather than another exclusive bloc.
As India marks eight decades of Independence, its strategic position has changed almost beyond recognition. Yet the central question of strategic autonomy remains. What India chooses to do with the strategic freedom it has built over eight decades may be the defining question of its next phase.
India has spent the past decade expanding its strategic choices — deepening ties with the US, Europe and Japan while maintaining important ties with Russia and strengthening engagement with the Gulf, Africa and Southeast Asia. Australia and New Zealand are also becoming increasingly important partners in the wider Indo-Pacific. At the same time, India has sought a larger voice for the developing world in international institutions. Strategic autonomy has traditionally been understood in diplomatic terms: the ability to maintain freedom of action without being drawn into competing power blocs. In an increasingly interconnected world, however, that freedom will depend just as much on economic choices.
The objective should be strategic interdependence — building sufficiently diverse relationships that dependence on any one country or economic system does not become a vulnerability. India is unusually well placed to pursue this. Its geography connects the Gulf and wider West Asia, the manufacturing economies of Asia, Africa across the Indian Ocean and the Eurasian space extending through Russia. The opportunity, therefore, is to become a connector between economies increasingly fragmented by geopolitical competition.
India’s relationship with Japan is extending into advanced manufacturing, technology, energy, semiconductors and critical minerals. Its engagement with the US is deepening across technology, investment, advanced manufacturing, energy and strategic cooperation, while its engagement with Europe is becoming increasingly economic and technological. Its relationships with the Gulf are expanding beyond energy into investment and connectivity. Australia and New Zealand add an important southern dimension to its wider Indo-Pacific engagement, while Southeast Asia provides pathways into wider Asian production networks.
Russia remains an important part of this equation. India’s continuing engagement with Moscow, alongside its deepening relationships with Washington, Tokyo, Europe and the Gulf, demonstrates that strategic autonomy gives India the flexibility to maintain important relationships across geopolitical divides.
China inevitably occupies a special place in this landscape. India’s answer cannot be either excessive dependence or complete separation. It will require strengthening domestic capabilities, diversifying supply chains and building partnerships elsewhere, while retaining space for engagement where interests permit.
India possesses another asset that few countries can match: a large, globally active and influential diaspora. Yet the diaspora can also present challenges, as political currents within these communities do not always align with India’s interests and can occasionally create sensitivities in its relations with host countries. The greater opportunity lies in nurturing the economic, intellectual and cultural connections the diaspora can create, while respecting its diversity and independence. In the emerging global economy, countries will increasingly seek multiple sources of energy, technology, capital, minerals and markets. India can contribute by helping create an open network rather than another exclusive bloc.
Ports, shipping routes, energy corridors, digital infrastructure, supply chains and trade agreements increasingly shape strategic influence. India’s challenge is to bring these strands together without turning them into a closed sphere of influence.
India’s economic rise will be more sustainable if other countries see themselves as participants in its growth rather than simply as markets for it. The value for India lies in making these relationships complementary rather than choosing among them. India’s leadership of the Global South can now move beyond representation in international forums towards creating an international economic environment in which developing countries have greater choices. India’s own experience is relevant here. It has moved from a relatively closed economic model towards deeper global integration while retaining a strong emphasis on domestic capability. The lesson is that openness and strategic autonomy need not be contradictory.
As the G20 meets again in Miami in December, India can continue to argue that the Global South should not merely seek greater representation within existing institutions, but a greater stake in shaping the economic networks and institutions of the future. An economically integrated Indian Ocean could allow countries such as Sri Lanka, Bangladesh and the Maldives to participate more deeply in regional supply chains, logistics, energy, tourism, technology and services. Influence based on shared prosperity is more durable influence based on dependence. India’s strategic opportunity, therefore, lies in becoming one of the principal connectors of a changing world.
(Milinda Moragoda is founder of the Pathfinder Foundation, strategic affairs think tank, and can be contacted via email @milinda.org.)
Courtesy Hindustan Times
Opinion
Financing Sri Lanka’s post-IMF development
by By Kasun Kariyawasam
and Shiran Illanperuma
In March 2027, Sri Lanka’s Extended Fund Facility with the International Monetary Fund (IMF) will expire. It is the seventeenth arrangement the country has entered into with the Fund since 1965. That number is not a footnote; it is the argument. Sixteen previous left the underlying structure of the economy intact – an economy that imports what it consumes, exports what it cannot process further, and borrows to cover the difference. Each programme ended, and the conditions that produced it reassembled themselves.
The seventeenth has been the most invasive. Approved on 20 March 2023, in the aftermath of the sovereign default and the uprising that followed, it arrived at a moment of maximum leverage for the creditor and minimum room for the debtor. Fiscal consolidation was achieved primarily through indirect taxation, so that the burden fell heaviest on the poor. Energy subsidies were withdrawn and utility pricing made cost-reflective, transmitting global price movements directly into household budgets and industrial input costs. Public investment was compressed, and public sector wages held below inflation for years.
The revenue target was met but the social consequences are now well documented.
First, poverty in Sri Lanka roughly doubled after 2022 and has remained near a quarter of the population – a level not seen for two decades. Malnutrition among children, school dropout, and the depletion of household savings and assets are the transmission channels through which a fiscal adjustment becomes a lost generation.
Second, the most mobile and most skilled workers – nurses, doctors, engineers, IT workers – have left in numbers that constitute a structural loss of productive capacity, subsidised by the Sri Lankan state and captured by the labour markets of the Gulf, East Asia, and the West.
Third, and the least discussed, is the loss of economic sovereignty. The Central Bank Act of 2023 grants the Central Bank of Sri Lanka operational independence under a narrow inflation-targeting mandate and prohibits the monetary financing of government deficits, removing an instrument of development finance that every industrialised economy used on its way up. The Economic Transformation Act of 2024 legislates the programme’s own quantitative targets as binding statutory obligations on all future governments.
Although the IMF programme ends in March 2027, the framework it installed does not. Austerity has been converted into a legal architecture. Any government that wishes to finance development after 2027 will find that the fiscal space to do so has been pre-emptively legislated away, and that the debt service profile steps up sharply from 2028 as the restructured bonds begin to amortise in earnest.
The instruments on the table
Three instruments are currently under discussion for managing the debt portfolio. Each is worth examining on its merits, and each shares a common limitation.
Macro-linked bonds.
The upside triggers are more likely to be hit than the underlying real economy warrants, because the reference variable is dollar GDP. A nominal appreciation of the rupee lifts dollar GDP without a single additional unit of output being produced. The control variable intended to guard against precisely this – a requirement of 11.5% cumulative real growth – is a low bar following two consecutive years of contraction, when the base effect alone does much of the work. The country may find itself paying creditors a growth premium for an exchange rate movement.
Climate swaps.
Debt-for-nature and debt for-climate arrangements can retire a portion of the stock and may unlock multilateral climate grants, which are concessional. But they do not address the productive structure that generates the deficit in the first place, and their conditionalities – conservation commitments over land, forest, and coastal zones – can cut directly against the industrial and energy build-out that any serious development strategy requires. A country cannot finance debt relief by constraining its own industrialisation.
Bond buybacks. Retiring restructured bonds converts a contingent, complex portfolio into a plainer one, which makes debt management tractable. If the bonds trade below face or recovery value, Sri Lanka retires debt at a discount. Lazard reportedly advised this course for Zambia, so the playbook exists. However, Sri Lankan bonds have performed strongly since the restructuring, which means the discount that would make a buyback attractive has largely disappeared. A buyback becomes cheap only if sentiment softens again, or if specific contingent tranches are marked down on fear of the upside triggers. Moreover, a sovereign buying back its own debt shortly after a restructuring invites the interpretation that it anticipates difficulty, which raises the cost of future issuance. Selective buybacks are worth pursuing, given the uncertain external environment and the value of a cleaner portfolio, but that they are a marginal improvement rather than a solution.
All three instruments manage the existing stock of debt. None of them generates new finance for development. They are exercises in liability management, and a country cannot manage its way out of underdevelopment. Sri Lanka needs relief and it needs capital, and the current conversation addresses only the first.
Building the domestic architecture
New financing without new institutions reproduces the crisis. Before Sri Lanka seeks capital abroad, it must rebuild the machinery that governs how it borrows.
The primary dealer system requires reconstruction on a proper legal footing. Before the crisis, the primary dealer network degenerated into a captive placement channel: when the central bank could no longer absorb unsold stock, dealers took paper on terms set by proximity rather than price. This is allocation by moral suasion, and it produced a domestic debt market that told the government nothing useful about the cost of its own borrowing. Rebuilding it with binding contractual obligations, genuine capital requirements, and published performance rankings – as China does for its own dealer network – would restore price discovery. A government that cannot read a true yield curve cannot manage a debt portfolio.
Sri Lanka also needs a published Medium-Term Debt Management Strategy (MTDS) with explicit targets for the composition of the portfolio: external against domestic, concessional against commercial, and fixed against floating rate. Borrowing at present is reactive, driven by immediate financing needs rather than by a strategic view of currency, rollover, and interest rate risk. An MTDS makes those trade-offs visible and accountable. It is unglamorous and it is prerequisite.
The China angle
Sri Lanka’s most underused financial asset is its existing relationship with China’s monetary and capital market infrastructure. A currency swap line of 10 billion RMB is already in place, renewed in 2025, and it functions almost entirely as a passive reserve backstop. It could be the foundation of a financing strategy.
Broaden the use of RMB for trade settlement.
The swap is presently constrained in its permitted uses. Extending it to cover bilateral trade invoicing and settlement would reduce the dollar dependency that is the primary transmission channel for external volatility into the Sri Lankan economy. Every import invoiced in dollars is a claim on reserves that fluctuates with US monetary policy, over which Sri Lanka has no influence whatsoever.
Request eligibility for the FIMA RMB repo facility.
China’s facility, announced in June 2026, provides eligible central banks with access to RMB liquidity against holdings of Chinese government bonds. For Sri Lanka this would mean an RMB reserve buffer that is genuinely liquid rather than notional, and a second source of emergency liquidity that does not require a Fund programme as its precondition.
Issue panda bonds in the onshore Chinese market.
Sri Lanka has already begun refinancing dollar-denominated loans from Chinese banks into RMB, which establishes the precedent and the relationships. Issuance in the Shanghai interbank market would lock in RMB funding at rates below what the Eurobond market will offer a recently defaulted sovereign, and it diversifies the creditor base away from the Paris Club and Western commercial holders whose collective action in 2022 and 2023 was itself a lesson in concentration risk.
Access the offshore dim sum market in Hong Kong.
The offshore CNH market is deep – new issuance reached $157.2 billion in 2025 – and is a plausible source of medium-term infrastructure financing on terms that do not carry policy conditionality.
Integrate with CIPS.
None of the above scales without payments infrastructure. Integration with China’s Cross-Border Interbank Payment System reduces exposure to dollar-clearing volatility, carries lower transaction costs than routing through SWIFT correspondent banking, and is what allows the swap facilities to be used at volume rather than symbolically.
Establish direct LKR–RMB settlement.
Building on the Indonesia–HKMA–PBoC framework of June 2026, a direct settlement mechanism for bilateral trade would give Sri Lanka a working channel into one of the largest markets in the world, and create a pipeline for foreign direct investment and other inflows that does not transit the dollar system at all.
Multipolarity as infrastructure
What Sri Lanka should build is a blueprint for a local currency settlement corridor that can be scaled to any partner. Begin with China, where the infrastructure already exists, and extend it to India, the country’s nearest neighbour and one of its largest trading partners, where rupee settlement arrangements are already operating with other states. The same institutional template – bilateral swap, direct settlement mechanism, payments system linkage, local currency invoicing – applies to any counterparty with which Sri Lanka has meaningful two-way trade.
The immediate prize is energy. A large share of Sri Lankan inflation originates in oil, transmitted through both the world price and the exchange rate at which it is paid. That volatility does not merely raise the cost of living; it creates genuine industrial hurdles, because manufacturers cannot plan around input costs that move with a currency they do not earn. Denominating energy imports in local currency terms would break one of the most damaging transmission channels between external shocks and domestic prices. For a country whose recent history is defined by a fuel queue, this is not an abstraction.
Multipolarity, understood correctly, is a portfolio strategy. A sovereign with settlement channels in several currencies, funding relationships across several capital markets, and reserve buffers denominated in more than one unit of account is a sovereign with options during a crisis. Sri Lanka in 2022 had none, and the terms it accepted in 2023 reflect that.
-
Features5 days ago“Wrap Me Up in My Blazer”— A Gentlemanly Bradby Reminiscence
-
Features4 days agoWhen Sri Lankan stories find their own voice
-
Features5 days agoJVP/NPP government as seen from outside by Lionel Bopage now domiciled in Australia
-
News4 days agoBASL takes exception to Justice Ganepola being denied a place in SC
-
Editorial6 days agoGovt. trying to dupe UN Rapporteur?
-
Features5 days agoProf. Savitri Goonesekere: What has she done?
-
Features5 days agoWorld Trade Politics: Canada rebuffs Trump’s tariff blackmail
-
News5 days agoLegal avenues explored to bring back Mahendran, aka Harjan Alexander
